<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-6180 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-6180</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-6180</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-123.html">extraction-schema-123</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <p><strong>Paper ID:</strong> paper-235592578</p>
                <p><strong>Paper Title:</strong> Exploring of Classification Methods for Early Detection of Alzheimer’s Disease</p>
                <p><strong>Paper Abstract:</strong> : Alzheimer's disease (AD) is a degenerative brain disease, a common health problem in elderly pesople which causes decline in memory and affected on nerve cells. AD has different stages like mild congestive impairment (MIC) (early stage), moderate (middle stage), severe (late stage) it is essential to detect AD early in MIC, so that pre-emptive measures can be taken. Significant research was carried out over the past century to diagnose and detect this disease early. The objective of the article is provide a review evaluation and critical analysis of the recent research work done to early diagnosis of AD using Machine Learning Strategies.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e6180.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e6180.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Age</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Advanced age</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chronological aging is identified in the paper as the strongest epidemiological risk factor for dementia and Alzheimer's disease, with incidence rising steeply with advancing age.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>demographic (age)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Increasing chronological age; paper reports dementia incidence rising from ~1% at ages 60–64 to 24–33% in those ≥85, implying age-related vulnerability to neurodegenerative processes underlying Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Population incidence statistics cited in the paper showing steep increase in dementia prevalence with age and projections of growing dementia burden as life expectancy increases.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiological/statistical summary (reported within review)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Population-level incidence estimates reported in the review (ages and percentages given: 60–64: 1%; ≥85: 24–33%); no single original cohort detailed.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper provides broad incidence figures but does not discuss causal mechanisms linking age to molecular pathology; age is a non-modifiable risk marker rather than a specific etiologic mechanism.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e6180.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Genetic risk profiles</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Genetic risk profiling for Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper notes genetic risk profiling as a proposed risk factor and as a diagnostic/stratification biomarker that can be analyzed but is costly and complex for large-scale screening.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Inherited genetic variants and risk alleles that increase susceptibility to AD; genetic profiling aims to quantify individual genetic risk (e.g., APOE and other loci, although specific genes are not detailed in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper states that genetic risk profiles are analysed in diagnostic recommendations and cites multimodal studies (referenced literature) incorporating genetic factors for predicting MCI-to-AD progression.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genetic testing / risk profiling</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Assays to detect known risk alleles or genetic signatures associated with increased AD risk; used as a biomarker or feature in multi-modal predictive models.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Risk stratification / predictive (preclinical or MCI to AD progression prediction in referenced studies)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced human cohort predictive studies (review cites works combining imaging, CSF, genetic factors)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in-paper; paper references studies that combine genetic factors with imaging and CSF for prediction (e.g., cited Varatharajah et al. 2019).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper explicitly notes genetic profiling is costly and complex to measure at large scales; no specific sensitivity/specificity reported here.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e6180.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular factors</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular pathology / vascular dementia (as differential and coexisting risk)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Vascular disease is mentioned as one of the other common causes of dementia and as a relevant differential/competing pathology when assessing cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>vascular</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Cerebrovascular disease and vascular lesions that can cause cognitive impairment and dementia either alone (vascular dementia) or contribute to AD symptomatology via reduced perfusion, infarcts, and white matter damage.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists vascular dementia among common dementia types and distinguishes it from AD; cites general epidemiological contribution to overall dementia burden.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mentioned in review context; no new primary data</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper does not parse how vascular pathology interacts causally with AD molecular pathology; presented as a separate/alternative cause of dementia rather than a proven cause of AD.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e6180.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Lewy body dementia</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Dementia with Lewy bodies (DLB)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>DLB is listed in the paper as another common type of dementia to consider in differential diagnosis when evaluating cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>alternative pathology / synucleinopathy (differential diagnosis)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Alpha‑synuclein aggregation (Lewy bodies) causing cognitive decline, visual hallucinations, and parkinsonism; mentioned here as a separate dementia syndrome to distinguish from AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper groups dementia types (AD, Lewy body, vascular, frontal lobe) and states AD is the most common cause; DLB included as well-known distinct pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Review mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper emphasizes diagnostic difficulty distinguishing dementia etiologies clinically; does not provide evidence about overlap or co-pathology rates.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e6180.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuropsych testing</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuropsychological and cognitive testing</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Standard clinical cognitive and neuropsychological assessments are described as central to clinical diagnosis of dementia/AD and to verifying intellectual deficits.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (diagnostic method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Neuropsychological / cognitive testing</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Formal cognitive tests and neuropsychological batteries assessing memory, executive function, language and visuospatial abilities used to detect cognitive impairment and support clinical diagnosis of dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not quantified in this paper; described qualitatively as the primary clinical diagnostic route but with known limits for etiologic specificity.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>MCI (mild cognitive impairment) and dementia stages; used to identify early symptomatic changes</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical assessment practices summarized in review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes there is no single clinical test that proves AD pathology; neuropsychological testing diagnoses cognitive impairment but is limited in determining underlying cause without biomarkers.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e6180.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Structural/functional imaging</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CT, MRI, PET, and SPECT neuroimaging</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review lists structural (CT, MRI) and functional/metabolic (FDG‑PET, SPECT) imaging modalities as important biomarkers/supportive diagnostic tools for AD and MCI detection.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection modality)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CT, MRI, PET (including 18F-FDG PET), SPECT</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CT/MRI assess structural brain changes (atrophy, ventricular enlargement); MRI used for volumetric/hippocampal analysis. FDG‑PET measures cerebral glucose metabolism reflecting neuronal activity; SPECT measures perfusion.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Performance metrics not uniformly reported in the review for all modalities; the paper cites literature where PET and MRI are used in predictive models (specific metrics in cited references but not detailed here).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Used across preclinical, MCI, and dementia stages depending on modality and analytic method; MRI and FDG‑PET commonly applied to MCI/early AD detection in cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced imaging studies and datasets; some cited papers apply deep learning to 18F-FDG PET and MRI (e.g., Ding et al. 2018 for PET).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Imaging datasets cited include OASIS (cross-sectional MRI, 416 subjects, ages 18–96, ~100 subjects >60 with very mild to moderate AD) and ADNI (mentioned).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes biomarkers (imaging) are costly and complex for large-scale use and that no single test definitively proves AD; imaging requires feature selection and careful analysis and may lack etiologic specificity without molecular biomarkers.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e6180.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid (CSF) biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review mentions CSF biomarkers among recommended diagnostic measures and cites literature where CSF interpretation is aided by decision-tree approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>biomarker (molecular)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper references works (e.g., Mofrad et al. 2019) showing decision trees can support interpretation of CSF biomarkers in AD, implying CSF measures are informative for diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF biomarker assays (e.g., Aβ, tau species — not enumerated in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Measures concentrations of disease-associated proteins (commonly amyloid‑beta and tau species) in cerebrospinal fluid to infer AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not quantified in this review; paper points to referenced studies for performance and to decision-tree methods to aid interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Often used for early/preclinical and MCI stages in referenced literature (not specified numerically here).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced diagnostic biomarker studies (decision-tree interpretation cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes biomarkers including CSF are costly/complex for large-scale measurement and does not supply sensitivity/specificity values; invasive lumbar puncture limits broad screening applicability.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e6180.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MRI + SVM</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Magnetic Resonance Imaging analyzed with Support Vector Machine classifier</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In the paper's reported comparisons, SVM applied to MRI-derived features achieved the highest classification performance among tested classifiers for discriminating AD/MCI from controls.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method combining imaging + ML)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>MRI-based feature extraction followed by Support Vector Machine classification</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Preprocessing and segmentation of T1-weighted MRI (feature extraction including structural/texture/volumetric measures such as hippocampal features), then supervised SVM classification to predict AD/MCI vs controls.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Reported in paper/Table IV: SVM TP rate = 0.976, FP rate = 0.021, precision = 0.976, recall = 0.976, F-measure = 0.975, MCC = 0.961, ROC area = 0.979, PRC area = 0.958. Overall accuracy reported as 97.6%.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>MCI (early stage) and very mild to moderate AD as present in the OASIS dataset used by the authors (early detection emphasis).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Computational classification study using human MRI dataset and machine learning (reported in this review; metrics derived using WEKA tool).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>OASIS cross-sectional MRI dataset referenced in paper: 416 subjects aged 18–96; clinically, ~100 subjects over age 60 diagnosed with very mild to moderate AD. Exact train/test split not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper acknowledges critical need to identify appropriate early-stage features and to reduce redundant features; results may be dataset-dependent (OASIS) and subject to overfitting/generalizability concerns; imaging cost and need for standardized acquisition limit broad clinical deployment.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e6180.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OASIS dataset</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Open Access Series of Imaging Studies (OASIS)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A publicly available cross-sectional and longitudinal brain MRI dataset used by the authors for studying AD and for training/testing ML classifiers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>MRI (dataset resource)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Contains T1-weighted MRI scans (3–4 per subject for cross-sectional set) used to extract structural features for classification of AD and controls.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Includes subjects clinically labeled from non-demented to very mild/moderate AD; suitable for MCI/early AD studies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Public human imaging dataset</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cross-sectional compilation of 416 subjects aged 18–96; subjects right-handed; ~100 subjects over age 60 with very mild to moderate AD.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>As a curated research dataset, population may not represent wider clinical diversity; acquisition parameters and demographic balance constrain generalizability of ML models trained on it.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e6180.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ADNI</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Alzheimer's Disease Neuroimaging Initiative (ADNI) database</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A large multimodal longitudinal research database of imaging, clinical, and biomarker data for AD research; mentioned as commonly used in AD diagnostic studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multimodal: MRI, PET, CSF, cognitive assessments, genetics (resource)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Provides standardized longitudinal MRI, PET, CSF and clinical data used to develop and validate imaging and biomarker-based detection/prediction models.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Dataset contains subjects spanning cognitively normal, MCI, and AD, enabling preclinical and progression studies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced longitudinal multicenter human research database</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified within this paper (ADNI referenced generally).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes genetic and biomarker measurements in such resources can be costly/complex; ADNI's selective recruitment and multi-site variability can affect generalizability.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6180.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e6180.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>18F-FDG PET deep learning</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>18F-fluorodeoxyglucose positron emission tomography (FDG‑PET) analyzed with deep learning</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Cited reference (Ding et al., Radiology) describes a deep learning model applied to 18F‑FDG PET for predicting AD diagnosis; the review mentions such PET deep-learning studies as part of the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Exploring of Classification Methods for Early Detection of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>18F-FDG PET with deep learning classification</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>FDG‑PET measures cerebral glucose metabolism; deep neural networks are trained to detect AD‑related metabolic patterns for diagnostic prediction.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not reported in this review (performance available in cited original paper but not summarized numerically here).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Used for diagnostic prediction of AD in cited literature (potentially early/symptomatic stages depending on study).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced deep learning imaging study (Radiology paper cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper does not provide the numeric performance or limitations beyond general statements that imaging-based biomarkers are costly and require careful feature selection.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning <em>(Rating: 2)</em></li>
                <li>Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics <em>(Rating: 2)</em></li>
                <li>A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain <em>(Rating: 2)</em></li>
                <li>Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks <em>(Rating: 1)</em></li>
                <li>Predicting Alzheimer's disease progression using multi-modal deep learning approach <em>(Rating: 2)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-6180",
    "paper_id": "paper-235592578",
    "extraction_schema_id": "extraction-schema-123",
    "extracted_data": [
        {
            "name_short": "Age",
            "name_full": "Advanced age",
            "brief_description": "Chronological aging is identified in the paper as the strongest epidemiological risk factor for dementia and Alzheimer's disease, with incidence rising steeply with advancing age.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "demographic (age)",
            "cause_description": "Increasing chronological age; paper reports dementia incidence rising from ~1% at ages 60–64 to 24–33% in those ≥85, implying age-related vulnerability to neurodegenerative processes underlying Alzheimer's disease.",
            "evidence_for_cause": "Population incidence statistics cited in the paper showing steep increase in dementia prevalence with age and projections of growing dementia burden as life expectancy increases.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "epidemiological/statistical summary (reported within review)",
            "study_population": "Population-level incidence estimates reported in the review (ages and percentages given: 60–64: 1%; ≥85: 24–33%); no single original cohort detailed.",
            "limitations_or_counterpoints": "Paper provides broad incidence figures but does not discuss causal mechanisms linking age to molecular pathology; age is a non-modifiable risk marker rather than a specific etiologic mechanism.",
            "uuid": "e6180.0"
        },
        {
            "name_short": "Genetic risk profiles",
            "name_full": "Genetic risk profiling for Alzheimer's disease",
            "brief_description": "The paper notes genetic risk profiling as a proposed risk factor and as a diagnostic/stratification biomarker that can be analyzed but is costly and complex for large-scale screening.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "Inherited genetic variants and risk alleles that increase susceptibility to AD; genetic profiling aims to quantify individual genetic risk (e.g., APOE and other loci, although specific genes are not detailed in this paper).",
            "evidence_for_cause": "The paper states that genetic risk profiles are analysed in diagnostic recommendations and cites multimodal studies (referenced literature) incorporating genetic factors for predicting MCI-to-AD progression.",
            "evidence_against_cause": null,
            "detection_method": "Genetic testing / risk profiling",
            "detection_method_description": "Assays to detect known risk alleles or genetic signatures associated with increased AD risk; used as a biomarker or feature in multi-modal predictive models.",
            "detection_performance": null,
            "disease_stage_detected": "Risk stratification / predictive (preclinical or MCI to AD progression prediction in referenced studies)",
            "study_type": "Referenced human cohort predictive studies (review cites works combining imaging, CSF, genetic factors)",
            "study_population": "Not specified in-paper; paper references studies that combine genetic factors with imaging and CSF for prediction (e.g., cited Varatharajah et al. 2019).",
            "limitations_or_counterpoints": "Paper explicitly notes genetic profiling is costly and complex to measure at large scales; no specific sensitivity/specificity reported here.",
            "uuid": "e6180.1"
        },
        {
            "name_short": "Vascular factors",
            "name_full": "Vascular pathology / vascular dementia (as differential and coexisting risk)",
            "brief_description": "Vascular disease is mentioned as one of the other common causes of dementia and as a relevant differential/competing pathology when assessing cognitive impairment.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "vascular",
            "cause_description": "Cerebrovascular disease and vascular lesions that can cause cognitive impairment and dementia either alone (vascular dementia) or contribute to AD symptomatology via reduced perfusion, infarcts, and white matter damage.",
            "evidence_for_cause": "Paper lists vascular dementia among common dementia types and distinguishes it from AD; cites general epidemiological contribution to overall dementia burden.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Mentioned in review context; no new primary data",
            "study_population": null,
            "limitations_or_counterpoints": "Paper does not parse how vascular pathology interacts causally with AD molecular pathology; presented as a separate/alternative cause of dementia rather than a proven cause of AD.",
            "uuid": "e6180.2"
        },
        {
            "name_short": "Lewy body dementia",
            "name_full": "Dementia with Lewy bodies (DLB)",
            "brief_description": "DLB is listed in the paper as another common type of dementia to consider in differential diagnosis when evaluating cognitive decline.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "alternative pathology / synucleinopathy (differential diagnosis)",
            "cause_description": "Alpha‑synuclein aggregation (Lewy bodies) causing cognitive decline, visual hallucinations, and parkinsonism; mentioned here as a separate dementia syndrome to distinguish from AD.",
            "evidence_for_cause": "Paper groups dementia types (AD, Lewy body, vascular, frontal lobe) and states AD is the most common cause; DLB included as well-known distinct pathology.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Review mention",
            "study_population": null,
            "limitations_or_counterpoints": "Paper emphasizes diagnostic difficulty distinguishing dementia etiologies clinically; does not provide evidence about overlap or co-pathology rates.",
            "uuid": "e6180.3"
        },
        {
            "name_short": "Neuropsych testing",
            "name_full": "Neuropsychological and cognitive testing",
            "brief_description": "Standard clinical cognitive and neuropsychological assessments are described as central to clinical diagnosis of dementia/AD and to verifying intellectual deficits.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (diagnostic method)",
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Neuropsychological / cognitive testing",
            "detection_method_description": "Formal cognitive tests and neuropsychological batteries assessing memory, executive function, language and visuospatial abilities used to detect cognitive impairment and support clinical diagnosis of dementia.",
            "detection_performance": "Not quantified in this paper; described qualitatively as the primary clinical diagnostic route but with known limits for etiologic specificity.",
            "disease_stage_detected": "MCI (mild cognitive impairment) and dementia stages; used to identify early symptomatic changes",
            "study_type": "Clinical assessment practices summarized in review",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes there is no single clinical test that proves AD pathology; neuropsychological testing diagnoses cognitive impairment but is limited in determining underlying cause without biomarkers.",
            "uuid": "e6180.4"
        },
        {
            "name_short": "Structural/functional imaging",
            "name_full": "CT, MRI, PET, and SPECT neuroimaging",
            "brief_description": "The review lists structural (CT, MRI) and functional/metabolic (FDG‑PET, SPECT) imaging modalities as important biomarkers/supportive diagnostic tools for AD and MCI detection.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection modality)",
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "CT, MRI, PET (including 18F-FDG PET), SPECT",
            "detection_method_description": "CT/MRI assess structural brain changes (atrophy, ventricular enlargement); MRI used for volumetric/hippocampal analysis. FDG‑PET measures cerebral glucose metabolism reflecting neuronal activity; SPECT measures perfusion.",
            "detection_performance": "Performance metrics not uniformly reported in the review for all modalities; the paper cites literature where PET and MRI are used in predictive models (specific metrics in cited references but not detailed here).",
            "disease_stage_detected": "Used across preclinical, MCI, and dementia stages depending on modality and analytic method; MRI and FDG‑PET commonly applied to MCI/early AD detection in cited studies.",
            "study_type": "Referenced imaging studies and datasets; some cited papers apply deep learning to 18F-FDG PET and MRI (e.g., Ding et al. 2018 for PET).",
            "study_population": "Imaging datasets cited include OASIS (cross-sectional MRI, 416 subjects, ages 18–96, ~100 subjects &gt;60 with very mild to moderate AD) and ADNI (mentioned).",
            "limitations_or_counterpoints": "Paper notes biomarkers (imaging) are costly and complex for large-scale use and that no single test definitively proves AD; imaging requires feature selection and careful analysis and may lack etiologic specificity without molecular biomarkers.",
            "uuid": "e6180.5"
        },
        {
            "name_short": "CSF biomarkers",
            "name_full": "Cerebrospinal fluid (CSF) biomarkers",
            "brief_description": "The review mentions CSF biomarkers among recommended diagnostic measures and cites literature where CSF interpretation is aided by decision-tree approaches.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "biomarker (molecular)",
            "cause_description": null,
            "evidence_for_cause": "Paper references works (e.g., Mofrad et al. 2019) showing decision trees can support interpretation of CSF biomarkers in AD, implying CSF measures are informative for diagnosis.",
            "evidence_against_cause": null,
            "detection_method": "CSF biomarker assays (e.g., Aβ, tau species — not enumerated in this paper)",
            "detection_method_description": "Measures concentrations of disease-associated proteins (commonly amyloid‑beta and tau species) in cerebrospinal fluid to infer AD pathology.",
            "detection_performance": "Not quantified in this review; paper points to referenced studies for performance and to decision-tree methods to aid interpretation.",
            "disease_stage_detected": "Often used for early/preclinical and MCI stages in referenced literature (not specified numerically here).",
            "study_type": "Referenced diagnostic biomarker studies (decision-tree interpretation cited).",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes biomarkers including CSF are costly/complex for large-scale measurement and does not supply sensitivity/specificity values; invasive lumbar puncture limits broad screening applicability.",
            "uuid": "e6180.6"
        },
        {
            "name_short": "MRI + SVM",
            "name_full": "Magnetic Resonance Imaging analyzed with Support Vector Machine classifier",
            "brief_description": "In the paper's reported comparisons, SVM applied to MRI-derived features achieved the highest classification performance among tested classifiers for discriminating AD/MCI from controls.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": "n/a (detection method combining imaging + ML)",
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "MRI-based feature extraction followed by Support Vector Machine classification",
            "detection_method_description": "Preprocessing and segmentation of T1-weighted MRI (feature extraction including structural/texture/volumetric measures such as hippocampal features), then supervised SVM classification to predict AD/MCI vs controls.",
            "detection_performance": "Reported in paper/Table IV: SVM TP rate = 0.976, FP rate = 0.021, precision = 0.976, recall = 0.976, F-measure = 0.975, MCC = 0.961, ROC area = 0.979, PRC area = 0.958. Overall accuracy reported as 97.6%.",
            "disease_stage_detected": "MCI (early stage) and very mild to moderate AD as present in the OASIS dataset used by the authors (early detection emphasis).",
            "study_type": "Computational classification study using human MRI dataset and machine learning (reported in this review; metrics derived using WEKA tool).",
            "study_population": "OASIS cross-sectional MRI dataset referenced in paper: 416 subjects aged 18–96; clinically, ~100 subjects over age 60 diagnosed with very mild to moderate AD. Exact train/test split not specified.",
            "limitations_or_counterpoints": "Paper acknowledges critical need to identify appropriate early-stage features and to reduce redundant features; results may be dataset-dependent (OASIS) and subject to overfitting/generalizability concerns; imaging cost and need for standardized acquisition limit broad clinical deployment.",
            "uuid": "e6180.7"
        },
        {
            "name_short": "OASIS dataset",
            "name_full": "Open Access Series of Imaging Studies (OASIS)",
            "brief_description": "A publicly available cross-sectional and longitudinal brain MRI dataset used by the authors for studying AD and for training/testing ML classifiers.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "MRI (dataset resource)",
            "detection_method_description": "Contains T1-weighted MRI scans (3–4 per subject for cross-sectional set) used to extract structural features for classification of AD and controls.",
            "detection_performance": null,
            "disease_stage_detected": "Includes subjects clinically labeled from non-demented to very mild/moderate AD; suitable for MCI/early AD studies.",
            "study_type": "Public human imaging dataset",
            "study_population": "Cross-sectional compilation of 416 subjects aged 18–96; subjects right-handed; ~100 subjects over age 60 with very mild to moderate AD.",
            "limitations_or_counterpoints": "As a curated research dataset, population may not represent wider clinical diversity; acquisition parameters and demographic balance constrain generalizability of ML models trained on it.",
            "uuid": "e6180.8"
        },
        {
            "name_short": "ADNI",
            "name_full": "Alzheimer's Disease Neuroimaging Initiative (ADNI) database",
            "brief_description": "A large multimodal longitudinal research database of imaging, clinical, and biomarker data for AD research; mentioned as commonly used in AD diagnostic studies.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Multimodal: MRI, PET, CSF, cognitive assessments, genetics (resource)",
            "detection_method_description": "Provides standardized longitudinal MRI, PET, CSF and clinical data used to develop and validate imaging and biomarker-based detection/prediction models.",
            "detection_performance": null,
            "disease_stage_detected": "Dataset contains subjects spanning cognitively normal, MCI, and AD, enabling preclinical and progression studies.",
            "study_type": "Referenced longitudinal multicenter human research database",
            "study_population": "Not specified within this paper (ADNI referenced generally).",
            "limitations_or_counterpoints": "Paper notes genetic and biomarker measurements in such resources can be costly/complex; ADNI's selective recruitment and multi-site variability can affect generalizability.",
            "uuid": "e6180.9"
        },
        {
            "name_short": "18F-FDG PET deep learning",
            "name_full": "18F-fluorodeoxyglucose positron emission tomography (FDG‑PET) analyzed with deep learning",
            "brief_description": "Cited reference (Ding et al., Radiology) describes a deep learning model applied to 18F‑FDG PET for predicting AD diagnosis; the review mentions such PET deep-learning studies as part of the literature.",
            "citation_title": "Exploring of Classification Methods for Early Detection of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "18F-FDG PET with deep learning classification",
            "detection_method_description": "FDG‑PET measures cerebral glucose metabolism; deep neural networks are trained to detect AD‑related metabolic patterns for diagnostic prediction.",
            "detection_performance": "Not reported in this review (performance available in cited original paper but not summarized numerically here).",
            "disease_stage_detected": "Used for diagnostic prediction of AD in cited literature (potentially early/symptomatic stages depending on study).",
            "study_type": "Referenced deep learning imaging study (Radiology paper cited).",
            "study_population": null,
            "limitations_or_counterpoints": "Paper does not provide the numeric performance or limitations beyond general statements that imaging-based biomarkers are costly and require careful feature selection.",
            "uuid": "e6180.10"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning",
            "rating": 2,
            "sanitized_title": "an_intelligent_alzheimers_disease_diagnosis_method_using_unsupervised_feature_learning"
        },
        {
            "paper_title": "Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics",
            "rating": 2,
            "sanitized_title": "predicting_shortterm_mcitoad_progression_using_imaging_csf_genetic_factors_cognitive_resilience_and_demographics"
        },
        {
            "paper_title": "A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain",
            "rating": 2,
            "sanitized_title": "a_deep_learning_model_to_predict_a_diagnosis_of_alzheimer_disease_by_using_18ffdg_pet_of_the_brain"
        },
        {
            "paper_title": "Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "decision_tree_supports_the_interpretation_of_csf_biomarkers_in_alzheimers_disease"
        },
        {
            "paper_title": "Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks",
            "rating": 1,
            "sanitized_title": "brain_mri_analysis_for_alzheimers_disease_diagnosis_using_an_ensemble_system_of_deep_convolutional_neural_networks"
        },
        {
            "paper_title": "Predicting Alzheimer's disease progression using multi-modal deep learning approach",
            "rating": 2,
            "sanitized_title": "predicting_alzheimers_disease_progression_using_multimodal_deep_learning_approach"
        }
    ],
    "cost": 0.0147465,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Exploring of Classification Methods for Early Detection of Alzheimer's Disease Exploring of Classification Methods for Early Detection of Alzheimer's Disease 5207 AUTHORS PROFILE
August 2019</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Management, TekkaliA P 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>India S N 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Tirumala Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Rajeswara Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>S 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Tirumala Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Rajeswara Rao 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>G Stalin Babu 
Dept of CSE
Dept of CSE
Dept of CSE
Aditya Institute of Technology
Narasaraopeta Engg College. Narasaraopeta
JNTUK University College of Engineering
VizianagaramA.P., India., A.PIndia</p>
<p>Exploring of Classification Methods for Early Detection of Alzheimer's Disease Exploring of Classification Methods for Early Detection of Alzheimer's Disease 5207 AUTHORS PROFILE</p>
<p>International Journal of Engineering and Advanced Technology (IJEAT)
6August 201910.35940/ijeat.F8215.088619Revised Manuscript Received on August 05, 20195206 Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP Research Scholar at JNTUK Kakinada in Department of CSE ,working as Assistant Professor in Aditya institute of technology and management , His area of research are image processing. Dr. S.N. Tirumala Rao, M.Tech ., Ph.D . He is working as Professor and Head of the Department of CSE, NarasaraoPeta Engineering College, Narasaraopet, Guntur(AP)-India. His Areas of research are Data Mining, Multi-Core and Parallel Programming and Computer Networks. He Published more than 20 National and International Journals and organized several National and International Conferences. Books Published: Advanced Unix Programming HI-Tech Publisher. Dr.R.Rajeswara Rao, Professor, Dept of CSE, JNTUK University college of Engg. Vizianagram(AP), India. His Areas of Interest: Speech Processing, Pattern Recognition, and Cloud Computing. He Published papers in several National and International Journals and also organized several National and International Conferences.Alzheimer diseaseClassificationMachine Learning
Abstract: Alzheimer's disease (AD) is a degenerative brain disease, a common health problem in elderly pesople which causes decline in memory and affected on nerve cells. AD has different stages like mild congestive impairment (MIC) (early stage), moderate (middle stage), severe (late stage) it is essential to detect AD early in MIC, so that pre-emptive measures can be taken. Significant research was carried out over the past century to diagnose and detect this disease early. The objective of the article is provide a review evaluation and critical analysis of the recent research work done to early diagnosis of AD using MachineLearning Strategies.</p>
<p>I. INTRODUCTION</p>
<p>Alzheimer's disease (AD) is a brain degenerative disease. It is a effect on human thoughts and work. It is also caused by the other diseases and conditions. Like a decline in memory, effected on nerve cells. Neuronal damage in Alzheimer's disease consequently impacts parts of the brain that allow an person to perform general body activities such as walking, swallowing eating etc [22]. Dementia is a term describing a variety of disorders, and there are many various types of dementia, such as Alzheimer's disease, dementia with Lowy bodies and vascular dementia, and others. Dementia of the type (AD) of Alzheimer's disease is by far the most common cause of dementia. It is widely acknowledged that early detection of dementia can lead to more effective intervention and morbidity constraint Their research concludes that people who encounter MCI criteria can be differentiated from healthy control subjects and those with very mild Alzheimer's disease. It appears that this group of subjects is a clinical entity that can described for therapy measures.</p>
<p>To date, most mental disorder types have been diagnosed based on clinical observation. In specific, those include recognition of disorders that tend to cluster together, the timing of disease appearance and their tendency to cure, persist or be chronic. Currently there are no effective and efficient diagnostic tools not available to detect Alzheimer's. Boise et al. acknowledge prior research of low levels of clinical evaluation and diagnosis and conclude a possible explanation for this in the originality of the symptoms of dementia associated with the constraints encountered by physicians in their clinical practice. Through modern neuropsychological and cognitive testing, Alzheimer's disease is clinically diagnosed and other evidence of intellectual deficiency is verified [25]. According to Dubois et al., in addition to the clinical measures, the recommendations for the diagnosis of Alzheimer's disease accentuate the role that distinct biomarkers can perform. Like Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed tomography (SPECT) etc., Genetic risk profiles are analysed although they are costly and complex to measure to large amounts of evaluations. There is no specific test that can prove whether a individual has Alzheimer's disease or not [23]. While physicians always can evaluate whether an person has dementia, the actual cause can be difficult to determine. Alzheimer's disease immunology and risk parameters make up 50% to 60% of all dementia situations in the modern world today. Some of the other causes of dementia are vascular, lewd body and frontal lobe.The incidence of dementia rises with age, from 1% in 60-64 to 24-33% in those 85 years of age or elder. Around 24.3 million persons suffered from dementia in 2001, which is predicted to double every two decades as life expectancy also rises to 81.1 million in 2040. Western Europe, the USA and China are the nations and regions of the globe that are most impacted.By 2040, 55.7% of the total population impacted will be ho me to these nations and regions</p>
<p>II. ALZHEIMER'S DIESES</p>
<p>A. Alzheimer's early signs and symptoms [20]</p>
<p> Memory loss that disrupts everyday life  Obstacles in planning or solving problems  Difficulty in understanding visual pictures and partial relationships  New issues with phrases in talking or writing  Reduced or poorly judged  losing the ability to retrace steps and Misplacing Things  Withdrawal from job or social activities  Difficulty in finishing familiar duties at home And at job or at leisure  Changes in state of mind and character</p>
<p>III. DATABASES</p>
<p>A. ADNI Database: ANDI [21] database having from known patient's data for Alzheimer's disease (AD) patients and the no disease patient's data and mild congestive implement (MIC) patients all information is there in the database. it mainly consider by the values are observed by the so many patients details of taken by the age, gender, education etc...In this database used to known the patient having Alzheimer's disease (AD) or not.</p>
<p>B. OASIS Database:</p>
<p>The Open Access Series of Imaging Studies (OASIS) [19] is originates from Dr. R. Buckner which enables free availability of the brain MRI data sets available to the research community. The OASIS dataset contains two categories of data a) Cross-sectional MRI data b) Longitudinal MRI data of demented and non-demented elderly adults [25]. In this paper we use OASIS Dataset for studying the Alzheimer's dieses. This set is a cross-sectional compilation of 416 subjects between the ages of 18 and 96. Three or four person T1-weighted MRI scans are included for each subject acquired in single scan sessions. The subjects are all right-handed, including males and females alike. Clinically, 100 of the subjects over the era of 60 were diagnosed with Alzheimer's disease (AD) very mild to moderate.</p>
<p>IV. MACHINE LEARNING STRATEGIES</p>
<p>"Machine learning is a data analysis technique that Automates the construction of analytical models.</p>
<p>It is a division of artificial intelligence based on the concept that, with minimal human interference, systems can learn from data, identify patterns and make decisions." ML is categorised into Supervised and Unsupervised these techniques are used to study of AD.</p>
<p>Figure 1: Machine Learning Techniques</p>
<p>A. Supervised Learning:</p>
<p>The supervised learning concept is constructed on a supervisor, teaches the learning Model to Use the trainingdata set to reference unlabeled data to a clas s label [17], In this model provide the both input and desired output and mapped between them Mapped is based on the data features acquired. Support vector Machine: "Support Vector Machine (SVM)" is a supervised algorithm for machine learning, used to solve the problems of classification and regression, the objective of SVM is to identify the ideal hyper plane for two classes between the training data. Kernel characteristics can be Use dto map the training set to a highlevel function space from i nput space.</p>
<p>Logistic Regression: Logistic Regression [17] is a supervised Machine Learning algorithm, it is used to solve the classification problems; LR Regression estimates the relationship between the dependent and two or more independent variables by estimating the probabilities using the Logistic function or also called Sigmoid function defined as Where Xi is the independent variable bi is The coefficients to be estimated in logistical regression by the fitting model.</p>
<p>In many AD research, LRC was used to justify discrimination against AD from other dementia types, early diagnosis, and AD progression.</p>
<p>B. Unsupervised Learning:</p>
<p>In Unsupervised Learning separate objects in various groups, no supervisor is provided i.e. no training data is available to use. Unsupervised Learning validates a mapping function to discover masked patterns and comparisons from unlabeled input datasets K-Mean: K-means clustering is unsupervised Machine learning strategy for grouping objects in a predefined set of K clusters. The process of K-Mean start with random center in data which are used as the beginning points for every cluster, and then tries to attach the nearest points to these canters. In several AD studies, K-means are used to cluster brain tissue, hippocampal and tumor segmentations.</p>
<p>V. LITERATURE SURVEY ON CLASSIFICATION TECHNIQUES FOR ALZHEIMER'S DISEASE DETECTION</p>
<p>In Table I, Table II and Table III </p>
<p>VI. PROCEDURE FOR CLASSIFICATION</p>
<p>The detail procedure of Classification of Brain MRI Images using machine Learning Techniques given in the below figure 2.</p>
<p>In first stage is Pre processing, it is an improvement of image data that suppresses the redundant and Unobtrusive distortions from image or enhance image features, different image pre processing techniques like linearization, Resizing, Thresholding, Normalization used in Study of AD.</p>
<p>In stage2 perform the image segmentation is a process of dividing image into various parts, the objective is change representation of image and faster to analyze, Segmentation of images used in numerous AD research, Sukanta Ghosh et al [15] Proposed a Fuzzy logic-based segmentation algorithm to solve the object Border detection of brain images, its topology-based algorithm is implemented with a novel Fuzzy rule-base and FIS targeted at detecting strong and weak edges of brain MRI images. The algorithm is helpful to early detection of AD by accurately identifying the of objects boundaries and tracing of abnormal tissue losses. The described fuzzy algorithm can be associated with a deep learning technique.</p>
<p>Figure2: Classification process</p>
<p>Yeliz Karaca et.al [16] implemented "Automatic RGB Color Segment Score Algorithm" It is an decision-making method that can be helpful for the diagnosis of brain MRI by decision rules. The technique implemented in 3 stages in stage 1 is Pre processing, to extract the brain from the MRI on a gray scale of AD, perform dilation and erosion morphological Operations. Stage2 is RGB segmentation stage, RGB values for color segmentation of threshold value (μi &gt; 15 pixels) has been defined using Otsu's technique through multi-level thresholding. Stage3 Post-processing stage: By implementing the CART algorithm, the decision rules are acquired dilation and erosion was chosen from the morphological image processing techniques. Stage 3 is One of the significant step in the AD diagnosis is feature extraction and Selection. It extracts specific features from pre processed image of different abnormal categories [ 18] , It's technique of decrease the original data by evaluating certain important characteristics of image. Different types of features used to diagnosis of AD like Structural features [8], wavelet based, Texture Features [9,12], volumetric feature [13], histogram based, color based, shape based, GLCM based from Brain MRI. In the classification stage it try to classify image based on their properties and assign a class label for the feature set. The classifiers into two categorized one is Binary classifiers ,other is Multi-Class classifiers ,In Binary classifier Classification with only 2 distinct classes or with 2 pre defined possible outcomes either presence or absence of abnormalities of brain image, Multi-Class classifiers is Classification with more than two distinct classes. In the Study of AD various classification methods are use like Support Vector Machine [7,10,13], convolution neural network [11], DNN [12], ANN [14], Decision tree, Naive Bayes K-nearest neighbor, Fuzzy methods are so useful to early detection of Alzheimer's detection.</p>
<p>The data set is divided into parts that are train and test data sets. Training data is used to calculate the patterns inherent the same. Testing is performed, and then observed if the patterns are in spot. For training and testing, similar data are required, generally extracted from same data set.</p>
<p>In the end, we have a anticipated disease based on the distinct algorithms with a final result of a disease predicted depending with certain symptoms of input.</p>
<p>A. Evaluation Metrics:</p>
<p>Evaluation metrics plays a significant role to discriminate among various machine learning models. We use Accuracy, Sensitivity and Specificity metrics to evaluate the performance of the Classifier.</p>
<p>Accuracy: Accuracy is one of the best metric to evaluating the performance of any classification method.</p>
<p>"Accuracy is the ratio of number of correct predictions to the total number of input samples."</p>
<p>By using the below formula we will calculate the Accuracy of any classifier.</p>
<p>Sensitivity:</p>
<p>Sensitivity (also called the True Positive Rate) is defined as the proportion of actual positives, which got predicted as the Positive, by considering all positive data points. </p>
<p>Specificity:</p>
<p>Specificity is defined is the proportion of true negative data points that are correctly considered as negative, by considering all negative data points.</p>
<p>Results:</p>
<p>In the table horizontally all the classifiers are mentioned and vertically all the performance Metrics mentioned on the basis of these parameters we can Conclude the best approach to identify the Alzheimer's disease. All the above mentioned parameters in the table are derived by using WEKA tool. In the below graph we took classification methods in the X-Axis, it Represents Accuracy, Sensitivity and Specificity of each classifier, the vales of Accuracy, Sensitivity and Specificity can be measured based the above said formula. Based on the observations the accuracy of SVM is 97.6 % .When Compare to the remaining classifiers SVM gives best performance  This article provided an extensive overview of Predication of Alzheimer's disease by using different machine learning based methods, also provided the process of classification of Brain images and a summary of the results acquired by various researchers to predict Alzheimer's disease. As recognized from the literature research, much research has been done in early detection of Alzheimer's disease, but the crucial need remains to identify Appropriate features that could detect Alzheimer are at an early stage .This article also provide various classifier and its performance evaluation on different metrics and finally concluded that SVM gives better results than other classifier.</p>
<p>Future research encompasses extracting reasonable set of features for early identification of Alzheimer's disease and also to decrease the insignificant and redundant conventional feature sets to enhance Alzheimer's methods effectively. . </p>
<p>Figure 3 :
3Comparison of various ClassifiersCONCLUSION:</p>
<p>includes summary of various research articles of 2019,2018,2017 years for Classification techniques for early Alzheimer's disease Detection ,it cohere which type of classifier , data source ,type of features are extracted and outcome of the research.International Journal of Engineering and Advanced Technology (IJEAT) 
ISSN: 2249 -8958, Volume-8 Issue-6, August 2019 </p>
<p>5208 </p>
<p>Published By: 
Blue Eyes Intelligence Engineering 
&amp; Sciences Publication </p>
<p>Retrieval Number F8215088619/2019©BEIESP 
DOI: 10.35940/ijeat.F8215.088619 </p>
<p>Table I :
ISummary of Classification approaches of Alzheimer's disease Diagnosis of 2017</p>
<p>Table II :
IISummary of Classification approaches of Alzheimer's disease Diagnosis of 2018</p>
<p>Table III :
IIISummary of Classification approaches of Alzheimer's disease Diagnosis of 2019Exploring of Classification Methods for Early Detection of Alzheimer's Disease </p>
<p>5209 </p>
<p>Published By: 
Blue Eyes Intelligence Engineering 
&amp; Sciences Publication </p>
<p>Retrieval Number F8215088619/2019©BEIESP 
DOI: 10.35940/ijeat.F8215.088619 </p>
<p>Table IV :
IVperformance metrics of various classifiers CLASSIFIER TP RATE FP RATE PRECISION RECALL F-MEASURE MCCROC 
AREA </p>
<p>PRC 
AREA </p>
<p>NAIVE 
BAYES 
0.914 
0.053 
0.909 
0.914 
0.911 
0.868 
0.978 
0.944 </p>
<p>LOGISTIC 
0.93 
0.06 
0.935 
0.93 
0.916 
0.89 
0.986 
0.973 </p>
<p>SVM 
0.976 
0.021 
0.976 
0.976 
0.975 
0.961 
0.979 
0.958 </p>
<p>RANDOM 
FOREST 
0.954 
0.04 
0.957 
0.954 
0.948 
0.93 
0.999 
0.995 </p>
<p>An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning. F Razavi, M J Tarokh, M Alborzi, Journal of Big Data. 6132Razavi, F., Tarokh, M. J., &amp; Alborzi, M. (2019). An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning. Journal of Big Data, 6(1), 32.</p>
<p>Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors. Y Varatharajah, V K Ramanan, R Iyer, P Vemuri, Cognitive Resilience, and Demographics. Scientific reports. 912235Varatharajah, Y., Ramanan, V. K., Iyer, R., &amp; Vemuri, P. (2019). Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. Scientific reports, 9(1), 2235.</p>
<p>Predicting Alzheimer's disease progression using multi-modal deep learning approach. G Lee, K Nho, B Kang, K A Sohn, D Kim, Scientific reports. 911952Lee, G., Nho, K., Kang, B., Sohn, K. A., &amp; Kim, D. (2019). Predicting Alzheimer's disease progression using multi-modal deep learning approach. Scientific reports, 9(1), 1952.</p>
<p>Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. R B Mofrad, N S Schoonenboom, B M Tijms, P Scheltens, P J Visser, W M Van Der Flier, C E Teunissen, Assessment &amp; Disease Monitoring. 11Alzheimer's &amp; Dementia: DiagnosisMofrad, R. B., Schoonenboom, N. S., Tijms, B. M., Scheltens, P., Visser, P. J., van der Flier, W. M., &amp; Teunissen, C. E. (2019). Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring, 11, 1-9.</p>
<p>k-Skip-n-Gram-RF: A Random Forest Based Method for Alzheimer's Disease Protein Identification. L Xu, G Liang, C Liao, G D Chen, C C Chang, Frontiers in genetics. 10Xu, L., Liang, G., Liao, C., Chen, G. D., &amp; Chang, C. C. (2019). k-Skip-n-Gram-RF: A Random Forest Based Method for Alzheimer's Disease Protein Identification. Frontiers in genetics, 10.</p>
<p>Multi-stream multi-scale deep convolutional networks for Alzheimer's disease detection using MR images. C Ge, Q Qu, I Y H Gu, A S Jakola, 10.35940/ijeat.F8215.088619Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619. 350Ge, C., Qu, Q., Gu, I. Y. H., &amp; Jakola, A. S. (2019). Multi-stream multi-scale deep convolutional networks for Alzheimer's disease detection using MR images. Neurocomputing, 350, 60-69. Published By: Blue Eyes Intelligence Engineering &amp; Sciences Publication Retrieval Number F8215088619/2019©BEIESP DOI: 10.35940/ijeat.F8215.088619</p>
<p>An improved machine learning technique based on downsized KPCA for Alzheimer's disease classification. S Neffati, K Ben Abdellafou, I Jaffel, O Taouali, K Bouzrara, International Journal of Imaging Systems and Technology. 292Neffati, S., Ben Abdellafou, K., Jaffel, I., Taouali, O., &amp; Bouzrara, K. (2019). An improved machine learning technique based on downsized KPCA for Alzheimer's disease classification. International Journal of Imaging Systems and Technology, 29(2), 121-131.</p>
<p>A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain. Y Ding, J H Sohn, M G Kawczynski, H Trivedi, R Harnish, N W Jenkins, . . Behr, S C , Radiology. 2902Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., ... &amp; Behr, S. C. (2018). A Deep learning model to predict a diagnosis of alzheimer disease by using 18F-FDG PET of the brain. Radiology, 290(2), 456-464.</p>
<p>Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. J Islam, Y Zhang, Brain informatics. 52Islam, J., &amp; Zhang, Y. (2018). Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. Brain informatics, 5(2), 2.</p>
<p>Early Diagnosis of Alzheimer's Disease from MRI Images Using PNN. N A Mathew, R S Vivek, P R Anurenjan, 2018 International CET Conference on Control, Communication, and Computing (IC4). IEEEMathew, N. A., Vivek, R. S., &amp; Anurenjan, P. R. (2018, July). Early Diagnosis of Alzheimer's Disease from MRI Images Using PNN. In 2018 International CET Conference on Control, Communication, and Computing (IC4) (pp. 161-164). IEEE.</p>
<p>Classification of Alzheimer's disease based on eight-layer convolutional neural network with leaky rectified linear unit and max pooling. S H Wang, P Phillips, Y Sui, B Liu, M Yang, H Cheng, Journal of medical systems. 42585Wang, S. H., Phillips, P., Sui, Y., Liu, B., Yang, M., &amp; Cheng, H. (2018). Classification of Alzheimer's disease based on eight-layer convolutional neural network with leaky rectified linear unit and max pooling. Journal of medical systems, 42(5), 85.</p>
<p>Deep Neural Network Classification method to Alzheimer" s Disease Detection. K K Gulhare, S P Shukla, L K Sharma, International Journals of Advanced Research in Computer Science and Software Engineering. 7Gulhare, K. K., Shukla, S. P., &amp; Sharma, L. K. Deep Neural Network Classification method to Alzheimer" s Disease Detection. International Journals of Advanced Research in Computer Science and Software Engineering ISSN: 2277-128X (Volume-7, Issue-6)</p>
<p>Alzheimer disease classification using KPCA, LDA, and multi-kernel learning SVM. S Alam, G R Kwon, International Journal of Imaging Systems and Technology. 272Alzheimer's Disease Neuroimaging InitiativeAlam, S., Kwon, G. R., &amp; Alzheimer's Disease Neuroimaging Initiative. (2017). Alzheimer disease classification using KPCA, LDA, and multi-kernel learning SVM. International Journal of Imaging Systems and Technology, 27(2), 133-143.</p>
<p>A machine learning based approach for detection of alzheimer's disease using analysis of hippocampus region from MRI scan. A Raut, V Dalal, 2017 International Conference on Computing Methodologies and Communication (ICCMC). IEEERaut, A., &amp; Dalal, V. (2017, July). A machine learning based approach for detection of alzheimer's disease using analysis of hippocampus region from MRI scan. In 2017 International Conference on Computing Methodologies and Communication (ICCMC) (pp. 236-242). IEEE.</p>
<p>A novel fuzzy pixel intensity correlation based segmentation algorithm for early detection of Alzheimer's disease. Sukanta Ghosh, Abhijit Chandrarajani, K Mudi, Multimedia Tools and Applications. Sukanta Ghosh , Abhijit ChandraRajani, K. Mudi," A novel fuzzy pixel intensity correlation based segmentation algorithm for early detection of Alzheimer's disease", Multimedia Tools and Applications,2018</p>
<p>Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm. Yeliz Karaca, Majaz Moonis, Abul Hasan Siddiqi, Ba¸sar Turan, ICCSA 2018. 10961Yeliz Karaca , Majaz Moonis, Abul Hasan Siddiqi, and Ba¸sar Turan,"Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm.": ICCSA 2018, LNCS 10961, pp. 92-106, 2018</p>
<p>Imaging and machine learning techniques for diagnosis of Alzheimer's disease. G Mirzaei, A Adeli, H Adeli, Reviews in the Neurosciences. 278Mirzaei, G., Adeli, A., &amp; Adeli, H. (2016). Imaging and machine learning techniques for diagnosis of Alzheimer's disease. Reviews in the Neurosciences, 27(8), 857-870.</p>
<p>Rashmi Patange A Survey on Classification Methods of Brain MRI for Alzheimer's Disease. Mamata Lohar, International Journal of Engineering Research &amp; Technology (IJERT). 705Mamata Lohar., Rashmi Patange A Survey on Classification Methods of Brain MRI for Alzheimer's Disease. International Journal of Engineering Research &amp; Technology (IJERT) ISSN: 2278-0181 Vol. 7 Issue 05, May-2018</p>
<p>. A Alzheimer&apos;s, Alzheimer's, A. (2015). 2015</p>
<p>Alzheimer's &amp; dementia: the journal of the. Alzheimer's Association. 113332Alzheimer's disease facts and figuresAlzheimer's disease facts and figures. Alzheimer's &amp; dementia: the journal of the Alzheimer's Association, 11(3), 332.</p>
<p>Alzheimer's Association. 2017Alzheimer's Association. (2017). 2017</p>
<p>Alzheimer's disease facts and figures. 13Alzheimer's &amp; DementiaAlzheimer's disease facts and figures. Alzheimer's &amp; Dementia, 13(4), 325-373.</p>
<p>The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. K Antila, J Lötjönen, L Thurfjell, J Laine, M Massimini, D Rueckert, . . Hviid Simonsen, A , Interface Focus. 32Antila, K., Lötjönen, J., Thurfjell, L., Laine, J., Massimini, M., Rueckert, D., ... &amp; Hviid Simonsen, A. (2013). The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus, 3(2), 20120072.</p>
<p>Comparative analysis of various machine learning algorithms for detecting dementia. D Bansal, R Chhikara, K Khanna, P Gupta, Procedia computer science. 132Bansal, D., Chhikara, R., Khanna, K., &amp; Gupta, P. (2018). Comparative analysis of various machine learning algorithms for detecting dementia. Procedia computer science, 132, 1497-1502.</p>            </div>
        </div>

    </div>
</body>
</html>